戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 of xenobiotic processing genes, and enhanced drug clearance.
2 ations returned to baseline values following drug clearance.
3 d between-child physiological variability on drug clearance.
4 t is distinct from the role of metabolism in drug clearance.
5  cytochrome P450 enzyme activity and biliary drug clearance.
6  Adolescent and adult dosing information and drug clearance.
7 ding substrate binding in P450s that mediate drug clearance.
8 rculating anti-Neu5Gc antibodies can promote drug clearance.
9 s effective in patients with higher rates of drug clearance.
10  with broad specificity and implications for drug clearance.
11 d that it inhibits SXR-mediated induction of drug clearance.
12 esented only a small portion of total parent drug clearance.
13 /kg, assessing elimination rates and time of drug clearance.
14 ted SXR and enhanced P-glycoprotein-mediated drug clearance.
15 ivities of SXR can be manipulated to control drug clearance.
16 h anticonvulsants and dexamethasone enhances drug clearance.
17  exposure to the drugs in patients with fast drug clearance.
18 ccount known relations between body mass and drug clearance.
19 rption, slower redistribution, and very slow drug clearance.
20 asma level, or (3) reciprocal apparent total drug clearance.
21 ) model of neuropathic pain, even well after drug clearance.
22 acil, mimicking the major host mechanism for drug clearance.
23 ose observed in males, potentially affecting drug clearance.
24 te clearance measurements can predict kidney drug clearances.
25 lected polymorphisms associated with reduced drug clearance adjusted for body mass index and the comp
26 mphatic systems contributes significantly to drug clearance after periocular injection; (3) corneal p
27 ants of these transporters can cause reduced drug clearance and adverse drug effects such as statin-i
28      This transport process is essential for drug clearance and also affects therapeutic efficacy.
29 d have additional distinctions pertaining to drug clearance and distribution.
30  (CYPs) are a major enzymatic determinant of drug clearance and drug-drug interactions.
31 plications for the role of SXR in regulating drug clearance and hepatic disorders associated with imp
32 atic metabolism for preclinical screening of drug clearance and hepatotoxicity.
33 d interracial differences in CYP3A-dependent drug clearance and in responses to many medicines.
34 localization, and function, thereby reducing drug clearance and increasing chemotherapy toxicity.
35              Induced neocapillaries increase drug clearance and limit tissue retention and subsequent
36 drug tolerance become counter-adaptive after drug clearance and result in symptoms of dependence.
37 f DXME in cancer cells significantly affects drug clearance and the onset of drug resistance.
38 t was not a clinically relevant predictor of drug clearance and thus did not justify the need for wei
39 ue to inefficient drug penetration and rapid drug clearance and toxicity can be improved by using a l
40 es the role of transport proteins in hepatic drug clearance and toxicity, and addresses the increasin
41 ements in ADC internalization and recycling, drug clearance, and alterations in signaling pathways an
42 ighest risk of medication overload, impaired drug clearance, and cognitive deficits.
43 lyte disorders, insulin resistance, impaired drug clearance, and mild coagulopathy.
44 ymes in cholesterol homeostasis and systemic drug clearance, and reveal novel regulatory pathways of
45  solubility and oral absorption, reduce free drug clearance, and selectively increase mTOR potency.
46 he iv bolus clearance of a drug, the in vivo drug clearance can be the drug delivery clearance contro
47              Adult and adolescent dosing and drug clearance data were obtained from FDA-approved drug
48 are studied to bridge the simulations to the drug clearance experients.
49 ion site is controlled and slow resulting in drug clearance from the body controlled by clearance fro
50       Pharmacokinetic analysis suggests that drug clearance from the CSF is biphasic, with a terminal
51 e clearance from the dosage form becomes the drug clearance from the patient.
52 , the pharmacokinetic parameters and urinary drug clearance in C. apella primates are remarkably simi
53                                              Drug clearance in children younger than 12 years is fast
54 ncogenic RAS/WNT activity promotes increased drug clearance in CRC and provides a practical path towa
55 ects and promote sustained actions following drug clearance in depressed patients who are treatment-r
56                             The mean time to drug clearance in infants was 4.0 months for adalimumab
57  with previous clinical reports of increased drug clearance in patients with untreated diabetes.
58  nuclear receptor SXR coordinately regulates drug clearance in response to a wide variety of xenobiot
59  of allometric scaling for the prediction of drug clearance in the adolescent population.
60 rophage depletion on tracer localization and drug clearance in vivo.
61  a useful surrogate for predicting secretory drug clearances in such patients.
62                                     For most drugs, clearance increases nonlinearly with total body w
63 re should be avoided for up to 1 year unless drug clearance is documented, and pregnant women should
64 drug delivery rate has no effect on measured drug clearance is not correct.
65  and sustained pharmacodynamic effects after drug clearance make this class of targeted protein degra
66   Tissue accumulation is dose-dependent with drug clearance occurring most rapidly from the brain and
67 tensity and age for all adjusted agents, and drug clearance of doxorubicin and free etoposide was als
68 unger patients, and compensate for increased drug clearance over time.
69 Anti-PEG-ASP was associated with accelerated drug clearance (P = 5.0 x 10(-6)).
70 redisposing DM1 livers to injury, MAFLD, and drug clearance pathologies that may jeopardize the healt
71                      Induction of a distinct drug clearance program by a high-affinity ligand for the
72 there is also the necessity to determine the drug-clearance properties of the polymorphic P450 enzyme
73 rate a remarkable ability to predict in vivo drug clearance rates of both rapid and slow clearing dru
74 or assay performance, false-negatives, rapid drug clearance rates, and difficulty in obtaining enough
75  high viral load and elevated antiretroviral drug clearance rates, which pose significant therapeutic
76 absorption and distribution and in enhancing drug clearance, respectively.
77 tion learning, and threat relearning, beyond drug clearance.SIGNIFICANCE STATEMENT Matrix metalloprot
78 the following liver transporters involved in drug clearance: SLC10A1, SLC22A1, SLC22A7, SLC47A1, SLCO
79     Body-surface area did not correlate with drug clearance; therefore, fixed daily dosing of 25 mg/d
80 ntrast, CED of free CPT-11 resulted in rapid drug clearance (tissue t(1/2) = 0.3 day).
81 use model, for which a strong correlation of drug clearance to humans has been demonstrated.
82                     However, the kinetics of drug clearance via CYPs varies significantly among indiv
83 d included studies if they contained data on drug clearance, volume of distribution, or drug concentr
84                                     Overall, drug clearance was 28.5% lower in female compared with m
85 endent in both nonhuman primates and humans; drug clearance was independent of dose but was higher in
86                                              Drug clearance was nonrenal and was not related to body-
87                                   Adolescent drug clearance was predicted from adult pharmacokinetic
88                            A rodent study of drug clearance with [(14)C]-acetaminophen was performed
89      Allometric scaling predicted adolescent drug clearance with an overall mean absolute percentage
90 repeated JAKi treatment continued even after drug clearance, with persistent changes in chromatin acc